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Andrew J. Hart,1 Madan H. Jagasia,1 Annette S. Kim,2 Claudio A. Mosse,2
Bipin N. Savani,1 Adetola Kassim1Measurement of minimal residual disease is routine in diseases such as chronic myelogenous leukemia, pre-
cursor B cell acute lymphoblastic leukemia, and acute promyelocytic leukemia because it provides important
prognostic information. However, the role of minimal residual disease testing has not been widely adopted in
multiple myeloma (MM), with other parameters such as the International Staging System (ISS) and cytoge-
netic analysis primarily guiding therapy and determination of prognosis. Until recently, achieving a complete
response (CR), as defined by the International Myeloma Working Group (IMWG) criteria, was rare in pa-
tients with MM. The use of novel agents with or without autologous peripheral blood stem cell transplanta-
tion (auto-PBSCT) has significantly increased CR rates, thus increasing overall survival (OS) rates. The
majority of patients with MM have persistent levels of residual disease that are below the sensitivity of
bone marrow (BM) morphology, protein electrophoresis with immunofixation, and light chain quantitation
even after attaining CR and will eventually relapse. Measurement of minimal residual disease by more sensi-
tive methods, and the use of these methods as a tool for predicting patient outcomes and guiding therapeutic
decisions, has thus become more relevant. Methods available for monitoring minimal residual disease in MM
include PCR and multiparameter flow cytometry (MFC), both of which have been shown to be valuable in
other hematologic malignancies; however, neither has become a standard of care in MM. Here, we review
current evidence for using minimal residual disease measurement for risk assessment in MM as well as incor-
porating pretreatment factors and posttreatment minimal residual disease monitoring as a prognostic tool
for therapeutic decisions, and we outline challenges to developing uniform criteria for minimal residual dis-
ease monitoring.
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6/j.bbmt.2012.05.009ing. In 1975, Durie and Salmon [1] described an MM
staging system using features such as tumor cell mass,
the presence of end-organ damage, osteolytic bone le-
sions, and elevated serum Ig levels. More recently, the
International Staging System (ISS) was developed that
describes disease burden based on b2-microglobulin
and serum albumin levels, with both having prognostic
significance at diagnosis [2]. Cytogenetic abnormali-
ties including 13q deletion and detection of t(4;14),
t(14;16), and del17p by fluorescence in situ hybridiza-
tion (FISH) have been shown to predict a less favorable
survival, and the International Myeloma Working
Group (IMWG) has proposed a new classification sys-
tem based on molecular and cytogenetic criteria [3].
Gene expression profiling has also recently been used
to determine high-risk populations but is not available
for widespread use [4,5]. The use of these molecular
and cytogenetic signatures to direct treatment, in the
context of other staging parameters, variable disease
manifestations, and expanding therapeutic options, is
still being validated.
Biol Blood Marrow Transplant 18:1790-1799, 2012 1791Minimal Residual Disease in Multiple MyelomaThe IMWG response criteria are based on (1)
serum and urine M-protein by electrophoresis and
immunofixation (IFX), (2) percentage of plasma cells
on bone marrow (BM) biopsy, and (3) serum free light
chains (sFLCs) [6]. The importance of achieving
a complete response (CR), with an associated benefit
in overall survival (OS), has been well-documented,
although data also show that development of CR has
the most significant benefit in only a small, high-risk
group of patients as defined by gene expression
profiling [7,8]. As CR rates have improved, more
rigorous definitions of response have been developed,
including stringent CR (sCR) by the IMWG
that incorporates sFLCs along with immuno-
histochemistry and immunofluorescent techniques to
establish plasma cell (PC) clonality [6]. It has been pro-
posed that the sFLC ratio, which has been shown at di-
agnosis to be an independent prognostic factor and
predict more aggressive disease, be incorporated into
the ISS to help improve risk stratification as well [9-
11]. The role of sFLC measurement as a minimal
residual diseasemarker will be further discussed below.
Improving CR rates, with associated increases in
OS and event-free survival (EFS), have made the mea-
surement and monitoring of minimal residual disease
in MM with more sensitive techniques a relevant pur-
suit. Microscopic BM examination, radiographic im-
aging, molecular, and flow cytometric techniques
have all been used for this purpose. Two very sensitive
techniques that have been studied with increasing fre-
quency during the past few years are PCR andmultipa-
rameter flow cytometry (MFC). However, for a variety
of reasons including the heterogeneity of the disease
and the technical complexity of some of the tech-
niques, minimal residual disease monitoring with
highly sensitive techniques has not become routine
clinical practice. Here, we review the use of these ap-
proaches and outline the challenges to developing uni-
form and available methods for minimal residual
disease measurement in MM.
Techniques for Assessing Minimal Residual
Disease in MM
Protein and imaging studies
Measurement of serum and urine paraprotein
levels with IFX, sFLC and urine free light chains,
and morphologic examination of the BM are all widely
available methods used to measure disease burden in
MM. One definition of CR is defined by the IMWG
as\5% PCs in the BM with negative serum and urine
IFX, and the clinical significance of achieving CR has
been well-described [6,7]. Data from the Total
Therapy trials have demonstrated the importance of
CR on long-term outcomes [12]. These treatment
regimens, though, are rigorous and may not be amena-
ble for use outside of large referral centers. A reportfrom the Korean Multiple Myeloma Working Party
demonstrated that achieving a CR/near CR (nCR) be-
fore autologous peripheral blood stem cell transplan-
tation (auto-PBSCT) significantly increased 2-year
OS from 70.9% to 86.6% compared with patients
achieving a partial response, providing data that
achieving CR has prognostic significance even before
high-dose therapy (HDT) and auto-PBSCT [13].
As BM biopsies are expensive, time-consuming,
and pose some risk to patients, it has been argued
that BM examination is not necessary in patients with
negative serum and urine electrophoresis and IFX
due to the low likelihood of increased PCs under these
circumstances [14]. However, the independent value of
BM examination has been examined in 2 studies. Data
from Chee et al. [15] showed in 92 patients that 14%
with negative IFX and 10% of patients with a normal
sFLC ratio had $5% BM PCs in the marrow, with
clonality demonstrated in 85% of patients with resid-
ual PCs [15]. In patients who are IFX-negative, they
found significantly improved OS from time of IFX-
negativity in patients with\5% total PCs compared
with those with $5% (6.2 versus 2.3 years; P 5 .01).
More recently, Fernandez de Larrea et al. [16] showed
in 35 patients after auto-PBSCT that the total number
of PCs present in patients in CR after auto-PBSCT
correlates with progression-free survival (PFS) but
not OS [16]. There was a nonsignificant difference in
median OS in patients with #1.5% PCs versus .5%
PCs (median OS not reached versus 9.7 years;
P5 .195). These results demonstrate that microscopic
assessment of the BM can have prognostic significance
regardless of the status of protein studies, although the
sensitivity of morphology alone is crude and limited by
the number of cells evaluated as well as sampling vari-
ability.
Imaging by fluorodeoxyglucose-positron emission
tomography (PET) has also been shown to have prog-
nostic significance, with a significant improvement in
PFS and OS in patients with 100% standardized up-
take value reduction compared with\100% standard-
ized uptake value reduction after treatment with
thalidomide-dexamethasone and auto-PBSCT in 1
study [17]. This held true even among patients other-
wise achieving a CR. Moreover, they demonstrated
a significant improvement in post-relapse OS if the
fluorodeoxyglucose-PET was negative versus positive
at 36 months. Although PET imaging is widely avail-
able, not all patients with MM will have PET-avid le-
sions, and heterogeneity of visual criteria and poor
interobserver reproducibility can be a problem with
interpretation of data from these imaging studies.
As CR rates have improved, more sensitive tech-
niques to measure the depth of response have been in-
vestigated. The sFLC ratio has been shown to have
prognostic significance at the time of diagnosis [9]. Us-
ing this ratio to monitor disease status during
1792 Biol Blood Marrow Transplant 18:1790-1799, 2012A. J. Hart et al.treatment has also been examined. Singhal et al. [18]
demonstrated a high degree of discordance between
the serum IFX and the sFLC ratio. Seventy-nine per-
cent of patients with a positive serum IFX had a normal
sFLC ratio, whereas only 6%of those with negative se-
rum IFX had an abnormal sFLC ratio, resulting in
a sensitivity and specificity for the sFLC ratio com-
pared with the serum IFX of 66% and 69%, respec-
tively [18]. Similarly, Giarin et al. [19] showed
discordance between sFLC ratios and IFX in patients
who received transplantation, although when using
a method that assesses total sFLC concentration (free
and bound), the concordance with IFX was better.
De Larrea et al. [20] reported that an abnormal
sFLC ratio is frequently (73% of CR patients) due to
presence of oligoclonal bands as part of normal im-
mune reconstitution after auto-PBSCT and is actually
associated with a good prognosis. The major value of
sFLC assessment is in patients with light chain only-
MM, due to lack of sensitivity of electrophoretic
methods to detect sFLCs [21]. Conversely, secretory
MM with fully assembled Igs may have normal sFLC
ratios in 5% of cases [22]. Thus, although the sFLC
ratio is now included in the definition of sCR by the
IMWG, it remains controversial how to incorporate
sFLC measurement into minimal residual disease
monitoring in MM. Similarly, other novel methods
to quantitate heavy chain Ig ratios are currently lacking
sufficient published data to support their routine use in
therapy monitoring at this time.
Minimal residual disease detection by PCR
Molecular monitoring of disease by MFC and
PCR has been commonly used in chronic myeloge-
nous leukemia, acute lymphoblastic leukemia, and
acute promyelocytic leukemia to help determine prog-
nosis and guide therapy [23-25]. Several PCR
techniques have been described for use in minimal
residual disease monitoring in MM. Use of PCR
allows the amplification of even single cells,
providing an exquisitely sensitive method to detect
minimal residual disease. However, minimal residual
disease testing in myeloma by PCR has proved
challenging for several reasons. The Ig heavy and
light chain (IGH, IGK, and IGL) loci have significant
somatic hypermutation (SHM), with an average
92.2% homology to the germline sequence for IGH
sequences, 93.9% for IGK, and 93.4% for IGL [26].
For this reason, standard primers designed against
the framework regions of the Ig genes occasionally
fail to bind to the patient template DNA sufficiently
well to result in amplification. As a result of SHM at
the binding sites of commercial primers, researchers
have attempted to develop highly sensitive molecular
assays for individual Ig rearrangements through the
design of allele-specific oligonucleotide (ASO)
primers, or primers based upon the patient’s individualsequence that is a product of both the specific rear-
rangement as well as any somatic hypermutation
[27]. PCR or even quantitative PCR can then be per-
formed using these primers, allowing highly sensitive
monitoring of the patient’s clone.
Table 1 summarizes data available from several
studies examining the role of PCR monitoring for
minimal residual disease in MM. Most early studies
used ASO-PCR methods [28-34]. However, in these
studies done before the era of more effective therapy
regimens, molecular minimal residual disease
measurement by qualitative PCR was found not to
be useful, as nearly all patients were positive for
residual disease at the molecular level aside from
some molecular remissions after PBSCT. An early
small case series demonstrated persistent molecular
remissions using qualitative, non–ASO-PCR in small
numbers of patients, suggesting the possibility of
cure, particularly with allogeneic SCT (allo-SCT)
[35]. Corradini et al. [31] described molecular remis-
sion with a qualitative PCR approach using ASO
primers in significantly more patients after allo-SCT
compared to auto-PBSCT [31]. Several studies have
also demonstrated the prognostic significance of min-
imal residual disease negativity by PCR after allo-SCT
[32,36-38].
More recently, semi-quantitative fluorescent and
real-time quantitative PCR (RQ-PCR) techniques,
primarily using ASO primers, were introduced to cor-
relate the level of the clone with clinical disease mani-
festations and outcomes [39-43]. These methods have
allowed very sensitive minimal residual disease
monitoring on the order of 1026 and permit trends
in levels to be followed rather than binary positive or
negative results. Using ASO RQ-PCR, Korthals
et al. [44] showed that low minimal residual disease
(\0.2% 2IgH/b-actin) measured before HDT and
auto-PBSCT was significantly associated with im-
proved median EFS and OS compared with high min-
imal residual disease. Sensitivity reached 1025 in 88%
of cases in this study using Taqman technology on the
LightCycler system (Roche, Mannheim, Germany).
Ladetto et al. [45] documented persistent molecular
remissions using either qualitative nested ASO-PCR
or ASO RQ-PCR in patients with MM treated with
bortezomib, thalidomide, and dexamethasone as con-
solidation after auto-PBSCT, with no patient in mo-
lecular remission relapsing after a median follow-up
of 42 months. An update to this study showed after
a median follow-up of 65 months, a 5-year OS of
100% for patients achieving minimal residual disease
negativity; no patient achieving molecular remission
has died [46].
Thus, PCR is a very sensitive technique that has
demonstrated prognostic significance after allo-SCT,
auto-PBSCT, and after consolidation therapy
with novel agents. Unfortunately, ASO-PCR–based
Table 1. Studies Examining PCR for Minimal Residual Disease Monitoring in MM
Authors No. of Patients Method Sensitivity Technical Success Rate Treatment Regimen CR Minimal Residual Disease Negativity Rate
Bird et al. [35] 5 PCR (not ASO) NR 100% Allo-BMT 100% 100% (3/3)
Corradini et al. [28] 18 ASO nested PCR NR 83% Auto-SCTor allo-SCT 50% (6/12) 0% (0/12)
Bj€orkstrand et al. [29] 15 ASO-PCR NR 62.5% Auto-SCT 2 53% (8/15) 80% (4/5)
Swedin et al. [30] 36 ASO semi-nested PCR 1024-1025 67% Auto-SCTor allo-SCT 42% (15/36) 21% (5/24)
Corradini et al. [31] 51 ASO-PCR 1025-1026 84% Auto-SCTor allo-SCT 71% (36/51) 7% (2/27, auto-PBSCT);
50% (7/14, allo-SCT)
Martinelli et al. [32] 26 ASO-PCR 1025 54% Allo-SCT 38% (26/68) 50% (7/14)
Martinelli et al. [33] 229 ASO-PCR 1025 88% (44/50) Auto-SCTor allo-SCT Allo 5 38% (26/68)
Auto 5 22.5% (36/161)
27% (12/44)
Cavo et al. [34] 13 ASO-PCR 1025-1026 100% Allo-SCT 92% (12/13) 69% (9/13)
Ladetto et al. [39] 29 Real-time PCR (not ASO)
ASO nested PCR
1024
1023-1024
66%
73% (FR1/ASO)
100% (FR3/ASO)
Auto-SCT NR NR
Davies et al. [66] 96 PCR (not ASO) 1024 NR Auto-SCT 53% (50/96) NR
Novella et al. [43] 36 PCR (not ASO)
ASO nested PCR
1024-1026
1024-1025
67% Auto-SCT 24% (7/29) NR
Corradini et al. [37] 70 ASO-PCR 1026 69% Allo-SCT 100% 33% (16/48)
Fenk et al. [42] 11 ASO real-time PCR 1024-1026 NR Auto-SCTor allo-SCT 45% (5/11) 27% (3/11)
Bakkus et al. [41] 87 ASO-PCR 1024 77% Auto-SCT 28% (19/67) 35% (21/60) #0.015%
65% (39/60) >0.015%
Raab et al. [38] 11 ASO real-time PCR 1024-1025 Allo-SCT 27% (3/11) 27% (3/11)
Ladetto et al. [45] 39 ASO nested
Real-time PCR (not ASO)
1026
5  1026
100% Auto-SCT 49% (19/39) 15% (6/39)
NR
Korthals et al. [44] 70 Real-time ASO-PCR 1024-1025 76% Auto-SCT 25% nCR before auto-PBSCT
29% nCR after auto-PBSCT
17% (9/53) before auto-PBSCT
21% (8/38) after auto-PBSCT
MM indicates multiple myeloma; CR, complete response; ASO, allele-specific oligonucleotide; NR, not reported; Allo-BMT, allogeneic bone marrow transplant; Auto-SCT, autologous stem cell transplant; Allo-SCT,
allogeneic stem cell transplant; Auto-PBSCT, autologous peripheral blood stem cell transplant; nCR, near complete response.
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1794 Biol Blood Marrow Transplant 18:1790-1799, 2012A. J. Hart et al.methods require sequencing each patient’s individual
clone(s) and developing primers specific to the patient’s
rearrangedandsomaticallymutated sequence, aprocess
impractical in the general clinical setting. However, in
2003, the BIOMED-2 Concerted Action group de-
signed a panel of primers, which have been extensively
applied to clonality testing in a number of B cell lym-
phomas [47-49]. Plasma cell neoplasms were not
included in the design or in the validation of the
primers. However, in other B cell malignancies, it was
demonstrated that the use of a combination of a panel
of IGH and IGK primers could identify a clonal
rearrangement in .98% of all cases, including post–
germinal center (therefore somatically hypermutated)
B cell neoplasms such as many diffuse large B cell
lymphomas and marginal zone lymphomas [50]. Al-
thoughplasma cell neoplasmswere avoided in these ini-
tial studies due to the known complication of SHM, the
use of multiple panels of primers against numerous loci
of the Ig genes, including nonfunctional rearrange-
ments more common in myeloma, increases the likeli-
hood that at least 1 primer pair will bind and allow
amplification. Subsequently, Martınez-Sanchez et al.
[51] have demonstrated that a set of 4 BIOMED-2
primer pairs alone was required to detect clones in
91%of patientswithmyelomausing unsortedBMaspi-
rates and that molecular minimal residual disease has
prognostic value for PFS after auto-PBSCT, albeit
with lower sensitivity than ASO-PCR and MFC.
Minimal residual disease detection by flow
cytometry
MFC is a technique increasingly described in the
literature as a viable method for minimal residual dis-
ease monitoring in MM, with several examples sum-
marized in Table 2. MFC can distinguish between
normal and malignant PCs by the aberrant expression
of cell surface markers in approximately 90% of pa-
tients [27]. MFC has become a useful tool in MM for
a variety of reasons. First, malignant PCs consistently
have aberrant immunophenotypes to distinguish them
from benign PCs. Second, these immunophenotypes
are relatively stable over time, allowing for consistentTable 2. Studies Examining MFC for Minimal Residual Disease Mo
Authors No. of Patients Method Sensitivity
Technic
Success R
San Miguel et al. [67] 87 4-color MFC 1024 100%
Paiva et al. [59] 295 4-color MFC 1024 100%
Liu et al. [58] 47 4-color MFC NR 97%
Mateo et al. [60] 685 4-color MFC NR 100%
Kumar et al. [68] 132 MFC NR NR
MFC indicates multiparameter flow cytometry; MM,multiplemyeloma; CR, com
autologous peripheral blood stem cell transplant; NR, not reported; VGPR, ver
mustine, melphalan, cyclophosphamide, prednisone (VBMCP) and vincristine, c
melphalan and auto-PBSCT.detection and quantification of the abnormal clone.
Third, modern MFC is sufficiently sensitive to detect
as few as 0.01% atypical plasma cells in a normal
BM [52,53]. The European Myeloma Network has
recommended that CD38, CD45, and CD138 be
tested simultaneously in at least 1 tube and included
in all tests if possible. CD19 and CD56 are the
minimum recommended markers for identifying
abnormal PCs (along with assessing cytoplasmic k/l
expression), with CD20, CD27, CD28, and CD117
preferably included to broaden applicability [54].
Most of the reported studies use 4-color MFC, an
older, less sensitive technique; however, 6-color and
even 8-color MFC have been described [52,55,56].
In 1999, Almeida et al. [57] described that
MFC 1 DNA ploidy using 13 different 3-color com-
binations can detect residual MM cells with sensitivity
up to 1025 at 3 months after auto-PBSCT. Rawstron
et al. [53], using CD19 and CD56 as markers of neo-
plastic PCs, demonstrated that patients with neoplastic
PCs at 3 months after auto-PBSCT had shorter PFS
than those with only normal PCs. MFC detected neo-
plastic PCs in 27% of patients in IFX-negative CR,
which predicted a shorter PFS. OS was significantly
higher in a low-risk group (normal PCs present 2 af-
ter auto-PBSCT) compared with high-risk patients
(100% versus 54%; P \ .0001). Liu et al. [58]
retrospectively demonstrated a significant PFS differ-
ence in patients who, before auto-PBSCT, had
#1.8% abnormal PCs compared with patients with
.1.8% abnormal PCs as measured by CD38/CD19/
CD45/CD56 expression (P5 .017). No OS difference
was demonstrated based on percent of PCs or achieve-
ment of CR/very good partial response (VGPR). Paiva
et al. [59] in a prospective analysis demonstrated by
multivariate analysis that minimal residual disease sta-
tus at day 100 after auto-PBSCT was the most impor-
tant prognostic factor for PFS (median 71 versus 37
months; P \ .001) and OS (median not reached
versus 89 months; P 5 .002) in patients treated on
the GEM2000 protocol. When minimal residual dis-
ease was examined by IFX in this study by univariate
analysis, there was a significant improvement in bothnitoring in MM
al
ate Treatment Regimen CR
Minimal Residual Disease
Negativity Rate
Auto-SCT 45% 36%
GEM2000 (auto-PBSCT) 50% 42%
Auto-SCT 66%
CR/VGPR
8%
GEM2000 (auto-PBSCT) 36% NR
Chemotherapy 22% to 47% 46%
plete response; Auto-SCT, autologous stem cell transplant; auto-PBSCT,
y good partial response; GEM2000, alternating cycles of vincristine, car-
armustine, doxorubicin, dexamethasone (VBAD) followed by high-dose
Table 3. Studies Examining Multiple Methods for Minimal Residual Disease Monitoring in MM
Authors
No. of
Patients Methods Sensitivity
Technical
Success Rate Treatment Regimen CR
Minimal Residual
Disease Negativity Rate
Rawstron et al. [53] 45 3-color MFC
PCR (not ASO)
1024
1023-1025
100%
64%
Auto-SCT 73% NR
56% (25/45)
Sarasquete et al. [27] 32 Real-time ASO PCR
4-color MFC
1025
1024
75%
90%
GEM2000 (auto-PBSCT) 58% 29% (7/24)
54% (13/24)
Martınez-Sanchez et al. [51] 53 Fluorescent PCR
(not ASO)
4-color MFC
1023-1024
1024
91%
94.5%
GEM2000 (auto-PBSCT) 51% 53% (28/53)
33% (17/51)
MM indicates multiple myeloma; CR, complete response; MFC, multiparameter flow cytometry; ASO, allele-specific oligonucleotide; Auto-SCT, autol-
ogous stem cell transplant; NR, not reported; GEM2000, alternating cycles of vincristine, carmustine, melphalan, cyclophosphamide, prednisone
(VBMCP) and vincristine, carmustine, doxorubicin, dexamethasone (VBAD) followed by high-dosemelphalan and auto-PBSCT; auto-PBSCT, autologous
peripheral blood stem cell transplant.
Biol Blood Marrow Transplant 18:1790-1799, 2012 1795Minimal Residual Disease in Multiple MyelomaPFS and OS in patients with negative IFX compared
with positive IFX at day 100 after auto-PBSCT; how-
ever, this was not significant by multivariate analysis.
The following 4-color Ab combinations were used
for MFC: CD38/CD56/CD19/CD45, CD138/
CD28/CD33/CD38, and CD20/CD117/CD138/
CD38. In more than 90% of cases, the CD38/CD56/
CD19/CD45 combination alone distinguished abnor-
mal MM PCs from normal PCs. Minimal residual dis-
ease negativity was defined as \1 MM PC in 104
normal PCs (sensitivity 1024). The same group further
described the prognostic significance of the presence
or absence of specific surface markers assessed by
MFC and showed that high-risk genetic markers by
FISH and persistent minimal residual disease by
MFC at day 100 after auto-PBSCT predicted short
CR, thus identifying patients with a poor prognosis
and high risk of early progression [60,61].
Thus, it has been prospectively demonstrated that
minimal residual disease measurement by MFC is sen-
sitive and predictive of survival outcomes. However,
MFC is a developing technology, with techniques still
variable among institutions and laboratories. Data is
also dependent on the quality of the aspirate and can
vary considerably depending on which aspirate sample
is analyzed [40]. Thus, further work needs to be done
to standardize techniques and criteria for minimal re-
sidual disease assessment by MFC in MM.
Comparison Studies
PCR and MFC have been directly compared in
several small studies (Table 3). Sarasquete et al. [27]
retrospectively examined minimal residual disease by
IFX, PCR, and MFC in 32 patients with MM in CR
or near CR after HDT and auto-PBSCT. The ASO
RQ-PCR technique was only applicable in 75% of pa-
tients, whereas 90% of samples could be analyzed by
MFC using Ab panels described in Paiva et al. [59].
In 25% of cases, PCR and MFC resulted in discordant
results. In all cases, PCR was positive with negative
MFC; no cases were positive by MFC and negative
by PCR. The discordance rates for either PCR or
MFC with IFX were 38%, with the more sensitivemethod varying from case to case. PFS was signifi-
cantly longer in patients with PCR#1024, but not sig-
nificantly longer in patients with negative IFX orMFC
\1024, although there was a trend toward significance
with MFC. Thus, in a small series of patients, minimal
residual disease negativity by ASO RQ-PCR predicted
longer PFS, whereas PFS was not significantly differ-
ent for patients with negative IFX and negative
MFC. A second study by Lioznov et al. [62] found
that MFC and ASO-PCR correlated extremely well
(r2 5 0.94; P \ .0001) in 69 samples, with only 1
sample unevaluable by ASO-PCR (.98% evaluable)
and none unevaluable by MFC.
Zhao et al. [63] compared multiple methods of
minimal residual disease monitoring in 121 BM sam-
ples. Immunohistochemistry was the most effective
method for detecting residual disease, with a 96% de-
tection rate, followed by limited MFC (3-color analy-
sis, CD38/CD45/k, CD38/CD45/l, CD138/CD45/
k, CD138/CD45/l) at 72%. Cytogenetics (15%),
FISH (50%), and detection of IgG and k light chain
gene rearrangements by qualitative PCRwith a limited
set of non-ASO primers (60%) were less successful. Al-
though this study is an interesting comparison of mul-
tiple techniques, the sensitivity of both MFC and PCR
are likely limited due to the use of older methodology.
Additionally, the majority of patients had residual dis-
ease at the time of BM examination, and no compari-
sons with serologic studies such as electrophoresis or
IFX were made. Paiva et al. [64] compared IFX,
sFLC, and immunophenotyping by MFC in 102 pa-
tients .65 years of age enrolled in the GEM05 .65
year trial. Three 4-color combinations (CD38/
CD56/CD19/CD45, CD38/CD27/CD45/CD28,
and ß2-microglobulin/CD81/CD38/CD117) were
used to detect phenotypic aberrancies in PCs. Seven
percent of patients with no minimal residual disease
by MFC (sensitivity #1024 to 1025) after induction
therapy (ie, immunophenotypic response) remained
IFX positive initially, although all subsequently be-
came IFX-negative. Discrepant results were common
among all methods tested. Those patients with immu-
nophenotypic response had significantly increased
1796 Biol Blood Marrow Transplant 18:1790-1799, 2012A. J. Hart et al.PFS and time to progression compared to those with
CR (IFX-negative and\5% PCs on BM biopsy) or
sCR (CR and normalization of the sFLC ratio); how-
ever, no OS benefit was noted.
Measurement of Minimal Residual Disease
in MM
The challenges
Measurement of minimal residual disease in MM
has been a challenging endeavor. Myeloma is a hetero-
geneous disease, making disease burden difficult to
measure and follow in many circumstances. Some pa-
tients present primarily with focal bone disease that is
readily seen on imaging but not easily evaluated in the
serum or by BM biopsy. Others have patchy BM in-
volvement with no evidence of focal bone involvement
or have evidence of diffuse marrow enhancement with
a paucity of serum and urinary paraprotein. Thus, de-
pending on their disease phenotype and molecular
characteristics, certain methods of minimal residual
disease measurement may not be applicable to some
patients with myeloma, making it difficult to develop
uniform guidelines for minimal residual disease mon-
itoring in this disease.
The depth and prognostic role of minimal residual
disease status after HDT/auto-PBSCT and consolida-
tion therapy in patients who have achieved CR or
VGPR after initial induction therapy is not well de-
fined. Electrophoretic or sFLC ratio techniques used
to detect PC products are valuable to detect disease
when there are clear differences between monoclonal
and polyclonal Igs, but these methods do have clear
limitations. After treatments that affect production of
all Igs, such as Total Therapy or auto-PBSCT, detec-
tion of residual disease by SPEP, UPEP, IFX, and
sFLC becomes less precise and complicated by limited
residual B cell repertoires, which lead to oligoclonal-
ity. There have been no large randomized studies in
MM comparing different treatment strategies that
have evaluated minimal residual disease detected by
MFC or PCR using either ASO or wider panels of con-
sensus primers. No studies prospectively examining
minimal residual disease using MFC or PCR have
been reported in patients treated with novel agents
with or without HDT/auto-PBSCT. Thus, more sen-
sitive methods for detecting minimal residual disease
are needed to compare the depth of remission using
different treatment strategies.
MFChas been slightly less sensitive than PCR [27].
These comparisons, however, are dependent upon the
specific methodologies used as well as which combina-
tions of primers (PCR) and antibodies (MFC) are used.
In both cases, the patchy nature of the disease makes
false-negative results a concern. New 6-color and 8-
colorMFC techniques have not uniformly been shown
to increase sensitivity beyond 1024 but can reduce costsand time to perform the analysis [52,55,56]. However,
in the presence of background polyclonal plasma cells,
MFC clearly has an advantage in the ability to identify
the abnormal population without any decrement
in analytical sensitivity, while sensitivity clearly
decreases in PCR-based methods unless ASO primers
are used. Due to the wide availability, ease, and rapid
turnaround time of MFC, this is likely to become the
method of choice for minimal residual disease mea-
surement in MM.
Timing of minimal residual disease assessment
Multiple questions remain to be answered, in-
cluding when is the best time to measure minimal
residual disease in MM. Korthals et al. [44] showed
that pre-auto-PBSCT minimal residual disease posi-
tivity by PCR was an independent prognostic factor
for both EFS and OS, with patients with low-
minimal residual disease having significantly im-
proved EFS and OS. However, this is a retrospective
study of a small number of patients treated with idar-
ubicin and interferon, agents that are not commonly
used since the development of new nonchemothera-
peutic agents. Paiva et al. [59] showed a significant in-
crease in OS and PFS in patients with no minimal
residual disease by MFC at day 100 after auto-
PBSCT. However, obsolete induction chemotherapy
regimens were also used in this study. Ladetto et al.
[45] demonstrated the value of minimal residual dis-
ease measurement by PCR after auto-PBSCT and
consolidation therapy with bortezomib and thalido-
mide. This study also included induction chemother-
apy (vincristine, doxorubicin, and dexamethasone)
with agents that are now uncommonly used. It thus
remains unclear when is the best time to integrate
minimal residual disease measurement into therapeu-
tic decision making.
Several important questions remain unanswered
based on the current literature. Should only patients
who are positive for minimal residual disease receive
HDT/auto-PBSCT, and can minimal residual disease
measurement be used to help determine whether this
therapy should be administered early or later in a pa-
tient’s treatment course? Recent data suggests that
OS is equivalent for early versus delayed auto-
PBSCT after induction therapy with immunomodula-
tory agents; however, minimal residual disease
measurement could help to identify patients that could
benefit more from 1 of these strategies [65]. Based on
minimal residual disease measurement, should some
patients receive consolidation therapy while others
should not? Can minimal residual disease monitoring
be used to determine the need for or duration of main-
tenance therapy? When is the best time after
auto-PBSCT to measure minimal residual disease?
Prospective clinical studies are needed to address these
and other unanswered management dilemmas.
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cance of minimal residual disease monitoring by
MFC, we are currently conducting a prospective study
of newly diagnosed patients with MM. Patients who
meet criteria for MM and who are candidates for
auto-PBSCT are treated with either bortezomib, lena-
lidomide, and low-dose dexamethasone (VRD) or bor-
tezomib, liposomal doxorubicin, and low-dose
dexamethasone (VDD) for 4 cycles, followed by
auto-PBSCT in those patients experiencing a partial
response or greater. MFC using three 7-color tubes
is performed on the initial pretherapy marrow aspirate
to determine the aberrant immunophenotypes of the
MM cells. In patients achieving$VGPR after 4 cycles
of induction therapy, minimal residual disease is being
assessed before and at 3 months after auto-PBSCT.
The aims of the study are to assess the frequency of
minimal residual disease negativity at the end of 4 cy-
cles of VRD or VDD and to assess the frequency of
minimal residual disease negativity at the end of
auto-PBSCT compared to before auto-PBSCT. If
current novel regimens like VRD or VDD achieve
a high incidence of minimal residual disease-
negativity, it may be reasonable to delay or not offer
HDT/auto-PBSCT in first remission and to proceed
with consolidation and/or maintenance therapy.The goal: Risk adapted therapy
Many techniques are available for the measure-
ment of disease burden in MM. Improving therapies
leading to increased CR rates have made prolonged
minimal residual disease-negative states achievable
even without allo-SCT. Radiographic studies, such
as PET imaging, as well as examination of the serum
and BM using highly sensitive techniques, such as
PCR and MFC, are valuable tools for measurement
of minimal residual disease in MM. Investigation of
minimal residual disease by PCR techniques in BM
of patients with MM achieving CR after auto-
PBSCT provides relevant information on residual
tumor load with a significant impact on the risk of re-
lapse. However, other minimal residual disease tech-
niques, such as MFC, yield similar prognostic
information with the advantage of being easier, faster,
and more widely available. Thus, it is reasonable to
think that MFC will become the routine technique
for assessing minimal residual disease in MM in clini-
cal practice. However, to reach this goal, additional
studies including larger numbers of patients and lon-
ger follow-up are required. At the moment, evidence
indicates that RQ-PCR and MFC are complementary
techniques in minimal residual disease evaluation for
MM. Both techniques show that decreases in the BM
tumor load below 1 malignant cell per 10,000 total
BM cells could be used as a target for the definition
of a molecular/immunophenotypic CR.Minimal residual disease measurement by PCR
andMFC seems to have prognostic value inMM; how-
ever, barriers to the uniform adoption of these tech-
niques remain due to the heterogeneity of the
disease, lack of availability of testing, and the relative
novelty of agents that commonly lead to durable CRs
in patients with MM. A pragmatic approach to cus-
tomizing disease management should include accu-
rately defining disease phenotypes as well as proper
risk stratification using validated pretreatment disease
prognostic factors and posttherapy disease monitor-
ing. An individualized minimal residual disease moni-
toring algorithm based on individual disease genetic
signature and pretreatment phenotype for each patient
with MM, with a goal to help predict outcome and
guide therapeutic decisions, will enable a risk-
adapted approach to disease management. More clini-
cal trials integrating these approaches are needed to
determine how best to use improved disease monitor-
ing methods and develop a truly personalized ap-
proach to MM therapy.ACKNOWLEDGMENT
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